The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index

BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy remains the standard of care for patients with previously treated non-small cell lung cancer. However, few reports have compared the clinical benefits of second-line ICIs alone with those of ICIs combined with other therapies, including anti-...

詳細記述

保存先:
書誌詳細
出版年:Front Oncol
主要な著者: Zhang, Ting, Yang, Xue, Zhao, Jing, Xia, Lixia, Wang, Qiyuan, Jin, Rui, Zhou, Lingxiao, Zhang, Bin, Zhao, Jun, Li, Huijie, Li, Wen, Xia, Yang
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2021
主題:
Oncology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8213016/
https://ncbi.nlm.nih.gov/pubmed/34150659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.690093
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料